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Glioblastoma is resistant to conventional treatments and has dismal prognosis. 23 
Despite promising in vitro data, molecular targeted agents have failed to improve 24 
outcomes in patients, indicating that conventional two-dimensional (2D) in vitro 25 
models of GBM do not recapitulate the clinical scenario. Responses of primary 26 
glioblastoma stem-like cells (GSC) to radiation in combination with EGFR, VEGF and 27 
Akt inhibition were investigated in conventional 2D cultures and a 3-dimensional (3D) 28 
in vitro model of GBM that recapitulates key GBM clinical features.  VEGF 29 
deprivation had no effect on radiation responses of 2D GSC but enhanced 30 
radiosensitivity of GSC cultures in 3D. The opposite effects were observed for EGFR 31 
inhibition. Detailed analysis of VEGF and EGF signalling demonstrated a 32 
radioprotective role of Akt that correlates with VEGF in 3D and with EGFR in 2D. In 33 
all cases, positive correlations were observed between increased radiosensitivity, 34 
markers of unrepaired DNA damage and persistent phospho-DNA-PK nuclear foci. 35 
Conversely, increased numbers of Rad51 foci were observed in radioresistant 36 
populations, indicating a novel role for VEGF/Akt signalling in influencing 37 
radiosensitivity by regulating the balance between non-homologous end-joining and 38 
homologous recombination mediated DNA repair.  Differential activation of tyrosine 39 
kinase receptors in 2D and 3D models of GBM explains the well documented 40 
discrepancy between pre-clinical and clinical effects of EGFR inhibitors.  Data 41 
obtained from our 3D model identify novel determinants and mechanisms of DNA 42 
repair and radiosensitivity in GBM, and confirm Akt as a promising therapeutic target 43 
in this cancer of unmet need. 44 
 45 
 46 
  47 
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Glioblastoma (GBM) is the most common and aggressive malignant primary brain 49 
tumour 1. Tumours exhibit inherent resistance to radiation and chemotherapy with 5 50 
year survival rates of ~4% 2,3. Radiation resistance of GBM has been attributed to a 51 
subpopulation of cancer cells termed ‘GBM stem-like cells’ (GSC) which express 52 
stem cell markers, can differentiate into different lineages and have potent 53 
tumorigenic capacity 4-10. To improve clinical outcomes, the molecular mechanisms 54 
underlying radio- and chemoresistance of GSC need to be elucidated. However, 55 
novel targeted agents that have shown pre-clinical activity in conventional GBM cell 56 
culture systems have consistently failed to achieve clinical efficacy.   57 
One explanation for the discrepancy between preclinical and clinical data is the 58 
widespread use of preclinical models that fail to recapitulate the in vivo scenario.  59 
Lack of clinical efficacy of new agents might be explained by misleading preclinical 60 
data generated in established cancer cell lines cultured in simplified two-dimensional 61 
(2D) in vitro systems, in which cells undergo profound phenotypical changes and 62 
exhibit markedly different responses to cytotoxic treatments 11-14. In the context of 63 
radiation therapy, 3D culture of lung and head & neck cancer cells embedded in 64 
laminin-rich extracellular matrix (lrECM) has been shown to promote radiation 65 
resistance compared to 2D culture 15,16.  Likewise, colorectal cancer cell lines 66 
cultured under similar 3D conditions exhibited changes in cellular morphology, 67 
phenotype and gene expression and were resistant to epidermal growth factor 68 
receptor (EGFR) inhibition compared to cells cultured in 2D conditions 17. We have 69 
recently demonstrated lack of response to the EGFR tyrosine kinase inhibitor 70 
erlotinib either alone or in combination with radiation in a novel 3D model of GBM 71 
consisting of patient-derived GSC grown on 3D-Alvetex® scaffolds (3D), whereas 72 
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radiosensitisation was clearly observed in 2D GSC 14.  These findings recapitulate 73 
those of clinical trials in GBM in which treatments targeting EGFR either through the 74 
tyrosine kinase inhibitors erlotinib or gefitinib, or the anti-EGFR antibody cetuximab 75 
showed very low response rates and in some cases yielded inferior outcomes and/or 76 
worse toxicity than standard of care 18-30, despite clear evidence of preclinical activity 77 
against established cell lines grown as 2D cultures. Taken together, these 78 
observations provide some insight into why results derived in conventional 2D cell 79 
culture systems are so often poorly predictive of clinical efficacy.  80 
Anti-vascular endothelial growth factor (VEGF) therapy has also been evaluated in 81 
GBM, yielding marginally better clinical outcomes. Hypoxia is a cardinal feature of 82 
GBM, and is associated with high levels of vascular endothelial growth factor (VEGF) 83 
31,32.  Increased VEGF expression correlates with poor prognosis and treatment 84 
resistance in GBM 33,34 and addition of anti-VEGF therapy (e.g. bevacizumab) to 85 
standard radio-chemotherapy increases progression-free survival but not overall 86 
survival 35,36. While anti-VEGF therapy was developed primarily to target the tumour 87 
vasculature, GBM cells also express VEGF receptor 2 (VEGFR2) and are thus 88 
potential targets 14,37, unlike normal brain in which VEGFR2 expression is 89 
undetectable.  Previous studies have reported protective effects of VEGF on GBM 90 
cells treated with paclitaxel or radiation 38 that were mediated via VEGFR2. VEGFR2 91 
inhibition has also been shown to reduce GSC viability and survival in vivo 37. We 92 
have recently added to this literature by showing that the anti-VEGF monoclonal 93 
antibody bevacizumab increases radiosensitivity in a customised 3D GSC system 94 
but has no effect in conventional 2D cultures 14.  95 
To interrogate these novel observations further, and elucidate the underlying 96 
mechanisms, we used our customised, validated 3D GBM model to investigate 97 
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whether the radiosensitising effects of VEGF inhibition are mediated via the DNA 98 
damage response (DDR). In this model, downregulation of VEGF signalling 99 
consistently induced a radiosensitive phenotype that was associated with aberrant 100 
NHEJ, inhibition of HR and accumulation of unrepaired DNA damage. We went on to 101 
show that the radiosensitising effects of VEGF depletion in 3D and EGFR inhibition 102 
in 2D cultures are mediated by the downstream signalling protein Akt. In addition, 103 
our data indicate that radiation induced changes in the sub-cellular localisation of 104 
EGFR are regulated by VEGF signalling.  105 
Materials and Methods 106 
Cell Culture and Radiation Treatment 107 
E2, R10 and G7 GBM cell lines were obtained from Colin Watts laboratory, derived 108 
from anonymised patient resection specimens as previously described 39.  Cell lines 109 
were routinely cultured on MatigelTM-coated plates (0.2347mg/ml in Adv/DMEM) in 110 
cancer stem cell optimised serum-free medium comprising Advanced/DMEM/F12 111 
medium (GIBCO) Supplemented with 1% B27 (Invitrogen), 0.5% N2 (Invitrogen), 112 
4g/ml heparin, 10ng/ml fibroblast growth factor 2 (bFGF,Sigma), 20ng/ml epidermal 113 
growth factor (EGF, Sigma) and 1% L-glutamine and used for experiments between 114 
passage 3 and 8.  For Alvetex® 3D cultures (3D-A), Alvetex® scaffolds were coated 115 
with diluted MatrigelTM as for 2D conditions.  Cells were irradiated using an RS225 116 
XStrahl machine, at 195 kV, 15 mA with a 0.5 copper filter, at a dose of 2.47 Gy/min.  117 
Cells were routinely tested every three months for mycoplasma always tested 118 
negative for mycoplasma contamination.  Authentication of cells with Illumina 119 
Infinium  Methylation Analysis in 2017. 120 
Mouse experiments 121 
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Female CD1 nude mice were anaesthetised using isofluorane and a 1cm incision 122 
was made through the skin along the length of the skull. A hole was drilled through 123 
the skull 3 mm posterior to the bregma, and 2 mm lateral to the midline.  Inoculation 124 
of tumour cells was performed using a digital stereotaxic frame (Harvard Apparatus). 125 
A programmable injector pump (Harvard Apparatus) was used to inject 1x105 GSC in 126 
5l PBS 3mm deep into the brain at a rate of 2l/min.   127 
Partial brain irradiation encompassing xenograft tumours was performed using the 128 
XStrahl small animal radiation research platform (SARRP). Mice were irradiated with 129 
220 kV (peak) X-ray beams at a dose of 4.8 Gy/min using a 5x5 mm collimator with 130 
parallel opposed beams under the guidance of cone-beam CT. 131 
 132 
Ethical approval  133 
Animal experiments were in compliance with all regulatory guidelines, as described 134 
in the Animals Act 1986 Scientific Procedures on living animals regulated by the 135 
Home Office in the United Kingdom. 136 
 137 
Clonogenic assays 138 
Cells were seeded on MatrigelTM-coated plates / 3D-Alvetex scaffolds (0.2374mg/ml). 139 
Seeding densities were as follows; 0-2 Gy – 300 cells / well (c/w); 3 Gy, 500 c/w; 4 140 
Gy, 800 c/w; 5-9 Gy, 1000 c/w.  18 hrs after seeding, cells were either sham 141 
irradiated or irradiated at indicated doses and incubated for 2.5 (2D) or 3 weeks (3D) 142 
prior to fixation with methanol and crystal violet staining  for 2D conditions, or 143 
thiazolyl blue tetrazolium bromide (MTT) staining followed by 2% paraformaldehyde 144 
(PFA)/PBS for 3D conditions.  Visible colonies were manually counted. Dose 145 
modifying factor (DMF) at 0.37% and 0.1% survival were calculated for each 146 
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treatment combination as well as sensitizing enhancement ratio (SER) to whole 147 
curve as in 40.  148 
For knockdown experiments, cells were transfected with respective siRNAs ( Table 149 
S1A) using Lipofectamine RNAiMax reagent according to manufacturer’s instructions. 150 
After 48 h incubation, cells were detached with Accutase, counted and seeded in 3D-151 
Alvetex Scaffolds at corresponding densities. 18 h after seeding, cells were 152 
irradiated at different doses (0-5 Gy) and incubated for 3 weeks. Clonogenic survival 153 
graphs represent mean plus SD of 3 independent experiments. Curves are fitted to a 154 
linear quadratic model and are normalised to respective 0 Gy control.  155 
For 96-well clonogenics, cells were seeded (G7 -100 c/w, G1 – 200 c/w), incubated 156 
for 16 h, treated with respective compounds, incubated for 2 h, irradiated at 0 or 3 157 
Gy, and incubated for 13 days prior to colony staining and fixing.   158 
Data was analysed using the median effect dose 159 
(https://pdfs.semanticscholar.org/6e6f/5f9d670c203ade39e49dec5920fc759d5b67.p160 
df) and Bonferroni’s statistical test. 161 
Immunofluorescence 162 
Cells (5 x 104 c/w) were seeded on Matrigel-coated coverslips or Matrigel-coated 163 
Alvetex® Scaffolds were exposed to erlotinib (1 M), MK-2206 with a chemical name 164 
of 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-165 
3(2H)-one hydrochloride [1:1] 41(1 M) or vehicle and treated with 5 Gy or sham 166 
irradiated. Cultures were fixed in 2% PFA/PBS at the indicated time points, 167 
permeabilised with 1% Triton/PBS, blocked with 2% BSA/TBS/0.5% Tween-20 and 168 
incubated with the respective primary antibodies, followed by appropriate secondary 169 
Research. 
on November 5, 2019. © 2019 American Association for Cancermct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 31, 2019; DOI: 10.1158/1535-7163.MCT-18-1320 
8 
 
Alexa Fluor 568 or 488 secondary antibodies (Invitrogen, 1:400).  Nuclei were 170 
counterstained with DAPI in mounting medium (VectaShield).  For H2AX, pDNA-PK 171 
and Rad51 foci quantification Z-stacks were obtained at 63× magnification on a 172 
Zeiss 780 confocal microscope. The number of nuclei analysed for each data point 173 
ranged from 30 to 50 nuclei.  Foci per nucleus were counted manually.  174 
For mitotic catastrophe, micronuclei and mitotic analysis, 3D cells were grown in 175 
Alvetex scaffolds for 4 days and then mock-irradiated or irradiated (5 Gy).  Cells 176 
were fixed with 4% paraformaldehyde 24 h after radiation treatment.  Scaffolds were 177 
immunostained for the mitotic marker phospho-S10 histone H3 (green) to visualise 178 
mitotic and mitotic catastrophe cells. DAPI was used to stain for DNA (blue).  An 179 
average of 350 nuclei / condition / experiment were identified randomly and scored. 180 
Percentages of cells displaying micronuclei, mitosis or mitotic catastrophe per 181 
nucleus were calculated.  Mean ± SEM of 3 independent experiments. P values 182 
calculated by t test. 183 
Protein extraction 184 
2D and 3D cells were exposed to the indicated treatments.  For 2D cultures, cells 185 
were incubated for 30 minutes in lysis buffer (1% SDS-Tris buffer in the presence of 186 
phosphatase and protease inhibitors), scraped from plastic and clarified using 187 
Qiagen columns.  For 3D cultures, scaffolds were incubated in lysis buffer for 25 min 188 
on ice, transferred to a rotating platform at 100 rpm and incubated for 5 minutes.  189 
Recovered lysate was clarified using Qiagen columns as for 2D lysates. Lysates 190 
were prepared using LDS sample buffer (Life Technologies) in the presence of 1 M 191 
DTT, blotted onto nitrocellulose membrane and probed with specific antibodies 192 
(Table S1B).  193 
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Differential radiosensitisation by erlotinib and VEGF in 2D and 3D cultures 196 
Elevated VEGF levels are a prominent feature of GBM in general and the GBM stem 197 
cell niche in particular, with concentrations reaching above 6000 pg/ml in these 198 
tumours 31. VEGF has been shown to promote self-renewal and survival of GBM 199 
cancer stem cells 37 but its impact on their radiation responses is not well 200 
characterized. To evaluate whether clinically relevant concentrations of VEGF 201 
modulate cellular responses to radiation in vitro, effects on clonogenic survival of 202 
three different patient-derived GBM cell lines (G7, E2 and R10) were measured 203 
under 2D GSC culture conditions and in our novel 3D model 14. Initially, we 204 
performed ELISA assays to measure secretion of VEGF. While all cell lines secreted 205 
VEGF in both hypoxic and normoxic conditions, concentrations were significantly 206 
lower than have been observed in GBM in vivo (Supplementary Fig. S1A).  To 207 
recapitulate clinically observed levels of VEGF, therefore, media were supplemented 208 
with human recombinant VEGF-A (3000 pg/ml). Whereas VEGF supplementation 209 
had no effect on clonogenic formation of 2D or 3D GSC in the absence of radiation 210 
treatment (Fig. 1A), and did not affect radiosensitivity of 2D cultures, VEGF 211 
deprivation was associated with a significant increase in radiation sensitivity of 3D 212 
cultures in all three cell lines (Fig. 1B and  Supplementary Table S2A). These data 213 
are consistent with our previous findings in which bevacizumab caused 214 
radiosensitisation in 3D cultures only 14.   215 
EGFR overexpression and/or gene amplification are also common features of GBM.  216 
Inhibition of EGFR activity with the specific tyrosine kinase inhibitor erlotinib 217 
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decreased phosphorylation of its active site (Y1173) at baseline and in irradiated 218 
conditions in both 2D and 3D GSC (Fig. 1C). However, radiosensitisation by erlotinib 219 
(1 M) was only observed in 2D cells (Fig. 1D and  Supplementary Table S2B), as 220 
previously demonstrated 14. A likely role for DNA repair in determining selective 221 
radiosensitisation of 2D cells by erlotinib was indicated by the observed delay in DSB 222 
resolution in 2D cells, as measured by sustained elevation of H2AX expression in 223 
protein extracts (Fig. 1C, compare lane 8 to lane 3). In marked contrast, erlotinib-224 
treated 3D GSC appeared to exhibit faster resolution of H2AX expression than 225 
controls (Fig. 1C, compare lane 11 to lane 16). 226 
To rule out the possibility that lack of radiosensitisation by erlotinib in 3D conditions 227 
was due to decreased drug delivery via compound adsorption to the scaffold, we 228 
assessed the radiosensitising activity of erlotinib alongside two known 229 
radiosensitisers, the PARP inhibitor olaparib and the ATM inhibitor KU-5593342, 230 
across a range of concentrations.  Reduced clonogenic efficiency was detected at 3 231 
Gy as expected (Supplementary Fig. S1B). Erlotinib failed to induce 232 
radiosensitisation of 3D cultures even at the highest concentration tested (10 M, 233 
Supplementary Fig. S1C), whereas radiosensitisation could be detected with 234 
olaparib and KU55933 at nanomolar and micromolar concentrations, respectively 235 
(Supplementary Fig. S1D and S1E).  These results validate our conclusion that 236 
erlotinib has no radiosensitising effect on 3D cells, and render any effect of the 237 
scaffold on drug activity very unlikely.  238 
Differential regulation of the downstream signalling molecule Akt in 2D and 3D 239 
GSC 240 
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In order to characterise the mechanisms by which VEGF and EGFR regulate GSC 241 
radiosensitivity we interrogated their key downstream signalling pathway Akt.  G7 242 
and E2 cells grown in 2D or 3D conditions were starved of growth factors for 48 243 
hours then induced either with EGF or with VEGF. While EGF treatment induced 244 
robust activation of EGFR and phosphorylation of Akt at the early time points in cells 245 
grown in 2D conditions, addition of VEGF showed no increment in Akt activation 246 
beyond baseline levels (Fig. 2A, left side blots).  In contrast, 3D cells showed robust 247 
Akt activation upon VEGF stimulation in both G7 and E2 cells (Fig. 2A, right hand 248 
blots).  EGF stimulation had a modest positive impact on Akt phosphorylation in G7 249 
3D cells at the early time points (Fig. 2A, left panels), remaining at baseline levels in 250 
E2 3D cells.  Expression of the three Akt isoforms at both mRNA and protein levels 251 
was observed in G7 and E2 cell lines (Supplementary Fig. S2A and S2B). 252 
Enrichment analysis43 of RNASeq data derived from G7 and E2 3D cells before and 253 
after radiation treatment revealed upregulation of genes involved in the Akt pathway 254 
(Supplementary Fig. S2C), supporting a likely role for Akt signalling in mediating 255 
radiation responses of 3D GSC. 256 
The divergent effects of EGFR inhibition on radiosensitivity of 2D and 3D GSC 257 
cultures prompted us to investigate how the radiation-erlotinib combination affected 258 
Akt signalling in these two systems. Erlotinib titration (0.5 M to 5 M) showed 259 
inhibition of EGFR activity in both 2D and 3D cultures, as demonstrated by 260 
decreased phosphorylation of its active site (Y1173) both at baseline and after 261 
radiation (Fig. 2B). However, this effect only translated into attenuation of Akt 262 
activation in 2D cells, having no effect on Akt activity in the 3D model in the G7 cell 263 
line and a reduced effect in E2 cells (Fig. 2B). This is in keeping with our previous 264 
observation that EGF plays only a minor role in Akt activation in the 3D system (Fig. 265 
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2A).  Time course analysis revealed inhibition of radiation induced Akt activity by 266 
erlotinib in 2D conditions at early time points (30 min to 3 hrs) (Fig. 2C, left panels), 267 
but no effect in 3D conditions (Fig. 2C, right panels).  Baseline levels of total Akt 268 
were similar in 2D and 3D cells (Fig. 2C). Taken together, our results suggest that 269 
Akt activity is differentially regulated in 2D and 3D conditions: by EGF signalling in 270 
2D conditions; and by VEGF signalling in 3D cells.  271 
Akt regulates radiation resistance in 2D and 3D GSC 272 
Having identified a pivotal role for Akt in downstream signalling from VEGF and 273 
EGFR, we next investigated its contribution to radiation resistance of 2D and 3D 274 
GSC using the specific Akt1/2 inhibitor MK-2206. Treatment of G7 and E2 GSC with 275 
MK-2206 (1 M) consistently inhibited Akt activity in all models, as demonstrated by 276 
reduced phosphorylation (Fig. 2D).  This effect was accompanied by 277 
radiosensitisation in all models (Fig. 3A and 3B, Supplementary Table  S2C). In the 278 
case of G7 cells, radiosensitisation was not further increased by erlotinib in 2D 279 
conditions (Fig. 3A, left graphs) or by VEGF deprivation in 3D conditions (Fig. 3B, left 280 
graph).  MK-2206 had more pronounced radiosensitising effects on E2 2D cells than 281 
erlotinib alone or indeed erlotinib in combination with MK-2206 (Fig. 3A, right graph 282 
and  Supplementary Table S2C), suggesting that other unidentified upstream 283 
signalling factors may be regulating Akt activity in this cell line.  In 3D E2 cells, MK-284 
2206 alone and VEGF-deprivation exhibited similar radiosensitising effects whilst the 285 
combination of MK-2206 and VEGF-deprivation induced further radiosensitisation 286 
(Fig. 3B, right graph and Supplementary Table S2C). These results indicate additive 287 
effects of VEGF and Akt inhibition in this cell line.  Subsequent experiments 288 
confirmed a dose response for the radiosensitizing effect of MK-2206 (Fig. 3C). 289 
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To validate that the radiosensitizing effects of MK-2206 were ‘on target’, the effects 290 
of Akt knockdown were evaluated using siRNA targeting of the three Akt isoforms.  291 
Downregulation of Akt1 and Akt3 expression at the protein level was detected in E2 292 
cells (Fig. 3D) and was associated with radiosensitisation of E2 3D GSCs (Fig. 3E 293 
and Supplementary Table S2D) validating the effects of MK-2206 treatment. 294 
Radiosensitising effects were also observed with the Akt inhibitor perifosine 295 
(Supplementary Fig. S2D)  further confirming the radiosensitising effects of this class 296 
of compounds.  Overall, these results indicate that radiation sensitivity in GSC is 297 
modulated by Akt activity irrespective of the growth conditions. 298 
VEGF deprivation and Akt inhibition are associated with reduced DSB repair 299 
and increased mitotic catastrophe in irradiated 3D GSC  300 
Radiation kills cells by damaging DNA and the integrity of the DNA damage 301 
response (DDR) is a key determinant of radiosensitivity. More specifically, DNA 302 
double strand breaks (DSB) are the most important cytotoxic lesions induced by 303 
radiation and are repaired either by the rapid but error-prone non-homologous end-304 
joining (NHEJ) pathway or by homologous recombination (HR) which is accurate but 305 
slower and requires the presence of a homologous sister chromatid 44,45. To 306 
investigate the mechanisms underlying the radiosensitising effects of VEGF 307 
deprivation and Akt inhibition, quantitative analysis of induction and resolution of 308 
radiation induced DSB was performed, using nuclear H2AX foci as markers of DSB.  309 
Delayed resolution of DSB was observed in the VEGF-deprived radiosensitive 310 
population compared to the radioresistant VEGF-supplemented 3D populations as 311 
shown by increased numbers of unresolved H2AX foci 24 hours after irradiation (Fig. 312 
4A and B). The possibility that this increase in H2AX foci was due to a larger 313 
proportion of VEGF-deprived cells being in the G2 phase of the cell cycle was 314 
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excluded by the fact that similar percentages of cells staining positive for the G2 315 
phase marker CENPF were detected in both conditions (Supplementary Fig. S3A 316 
and S3B, VEGF-enriched 24.44% ±7.62, VEGF-deprived 22.985% ±1.138). No 317 
significant differences in H2AX foci were observed in VEGF-deprived or 318 
supplemented cells in the absence of radiation (Fig. 4C).  A delay in DSB resolution 319 
was also observed in 3D (Fig. 4D) and 2D cells (Fig. 4E) treated with MK-2206 (1 320 
M). More detailed analysis revealed MK-2206 to be associated with increased 321 
numbers of H2AX foci 30 minutes after radiation, suggesting either increased 322 
induction of DSB or impairment of early (or ‘fast’) DSB repair, and at the 24 hour time 323 
point (Fig. 4E; representative images in Supplementary Fig. S3C). Unirradiated 324 
GSCs treated with MK-2206 exhibited a small but statistically significant increase in 325 
median number of foci compared to vehicle at the 24 hour time point, indicating a 326 
possible role for Akt in repair of DSB arising from endogenous sources (Fig. 4F).   327 
Levels of unresolved DSB at 24 hours correlate with radiation sensitivity both in vitro 328 
and in vivo 44 and have potential to cause cell death by a number of mechanisms 329 
including mitotic catastrophe 46,47. To understand the cell death mechanisms by 330 
which inhibition of VEGF or Akt signalling enhances radiosensitivity, quantification of 331 
mitotic cells and those undergoing mitotic catastrophe was performed using the 332 
specific mitotic marker histone H3 phosphorylated at serine 10 (pS10-H3). Cells 333 
undergoing mitotic catastrophe were readily detected as fragmented, pS10-H3 334 
positive nuclei (Fig. 4G, red arrows). Whereas numerous cells undergoing mitotic 335 
catastrophe were identified in VEGF-deprived 3D cultures 24 hours after irradiation, 336 
very few were observed in VEGF-enriched 3D conditions (Fig. 4G and H).  An 337 
increase in the number of cells exhibiting micronuclei was also observed in the 338 
VEGF-deprived populations (Fig. 4H), consistent with the hypothesis that cells 339 
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completing mitosis in the presence of unrepaired DNA DSBs generate severe 340 
structural chromosomal defects and will eventually succumb. Similar increases in 341 
micronuclei were observed in irradiated cells treated with MK-2206 (Supplementary 342 
Fig. S3D). Together these results demonstrate that VEGF-deprived 3D cells and Akt 343 
inhibited cells are less efficient at repairing radiation induced DNA damage and 344 
hence accumulate unresolved DNA DSB that lead eventually to cell death by 345 
mechanisms including mitotic catastrophe. 346 
Aberrant NHEJ characterised by persistent DNA-PKcs binding at DSB is 347 
associated with the radiosensitising effects of VEGF deprivation or MK-2206 348 
treatment 349 
Cell survival after radiation is determined by both induction of DNA damage and the 350 
repair processes that follow. Efficiency and integrity of DSB repair depend on 351 
appropriate engagement of either NHEJ or HR, and it has been reported that cancer 352 
cells can be susceptible to aberrant DSB repair as a consequence of over-353 
expression or inappropriate activation of NHEJ proteins 48,49. Approximately 80% of 354 
X-ray-induced DSBs are repaired within 2-3 hours by the NHEJ pathway, of which 355 
DNA-PKcs is a major catalytic component 50. Of direct relevance to our experiments, 356 
Akt has been shown to activate DNA-PKcs activity in response to radiation 51,52. To 357 
investigate whether delayed resolution of DSBs in the radiosensitised populations 358 
was due to diminished NHEJ repair, we quantified the number of phosphorylated 359 
DNA-PKcs foci per nucleus in G7 and E2 cells. Unexpectedly, the number of pDNA-360 
PKcs foci 0.5 hours after radiation (5 Gy) was found to be significantly increased in 361 
VEGF-deprived, radiosensitive 3D populations compared to the more radioresistant 362 
VEGF-enriched 3D cells (Fig. 5A and B). In contrast, VEGF treatment did not affect 363 
the number of pDNA-PKcs foci in 2D cultures (Supplementary Fig. S3E). 364 
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Quantitative analysis of pDNA-PKcs kinetics over a 24 hour period after radiation 365 
treatment showed increased numbers of foci throughout the time course in the 366 
radiosensitive VEGF-deprived 3D GSC populations compared to 3D cells grown in 367 
the presence of VEGF (Fig. 5A and B).  We hypothesized that the presence of large 368 
numbers of unresolved pDNA-PKcs foci in VEGF-deprived 3D cells at the 24 hour 369 
time point was indicative of ineffective attempts at DSB repair, an interpretation that 370 
is supported by the H2AX data shown in Fig. 3 and the additional observation that 371 
these unresolved pDNA-PKcs foci were larger than those observed at earlier time 372 
points (Fig 5A, compare 0.5 hrs (-) VEGF image with 24 hrs (-) VEGF image).  373 
Consistent with our previous results, we observed a similar increase in the number of 374 
pDNA-PKcs foci (red) at the 24 hrs time point in MK-2206 treated 3D cells compared 375 
to controls (Fig. 5C). These foci co-localised with H2AX foci (green), indicating that 376 
pDNA-PKcs molecules were accumulating at DSB (Fig. 5C). In order to validate that 377 
these DNA-PK foci mediated radiosensitising effects were occurring downstream of 378 
VEGF and Akt, clonogenic assays were performed in cells depleted of DNA-PKcs by 379 
siRNA targeting. Following siRNA transfection, E2 cells exhibited a significant 380 
reduction in DNA-PKcs protein expression and were more radiosensitive than cells 381 
transfected with scrambled siRNA (Fig. 5D). Importantly, whereas MK-2206 382 
mediated radiosensitisation persisted in cells expressing scrambled siRNA, no 383 
additional radiosensitisation was observed in cells depleted of DNA-PKcs (Fig. 5D 384 
and Supplementary Table S2E). These data provide compelling evidence for a novel 385 
role for VEGF/Akt signalling in influencing radiosensitivity by interfering with NHEJ 386 
through persistent binding of DNA-PKcs to DSB. We postulate that this role has not 387 
been identified previously because mechanistic studies have generally been 388 
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conducted in 2D in vitro cultures in which EGFR signalling is upregulated at the 389 
expense of VEGF signalling. 390 
Homologous recombination repair is regulated by VEGF in 3D cultures 391 
It is well established that the NHEJ and HR pathways ‘compete’ for access to and 392 
repair of DSB under certain circumstances, and inhibition of NHEJ has been shown 393 
to enhance DSB repair under certain conditions by promoting HR 53. To test the 394 
hypothesis that persistent binding of pDNA-PKcs to DSB inhibits HR repair function, 395 
3D cells in the presence or absence of VEGF were fixed 3 hours after radiation and 396 
stained for the key HR protein Rad51. While considerable numbers of Rad51 foci per 397 
nucleus were detected in the radioresistant VEGF enriched 3D cells, far fewer foci 398 
were visible in the radiosensitive VEGF-deprived 3D cultures at the same time point 399 
(Fig. 5E and F).  These findings were supported by similar observations when cells 400 
were stained for an alternative HR protein BRCA2 (Supplementary Fig. S3F).  This 401 
effect cannot be explained by a difference in cell cycle distribution as the proportion 402 
of CENPF positive G2 cells was not affected by VEGF addition (Supplementary Fig. 403 
S3A and S3B). Consistent with the tenet that HR is cell cycle phase specific, 404 
functioning only in S and G2 phases during which a sister chromatid DNA template is 405 
available for repair, the proportion of nuclei staining positive for Rad51 was not 406 
statistically significant to the proportion of CENPF positive cells under the same 407 
conditions (Supplementary Fig. S3G). These data indicate that, in this 3D model, 408 
VEGF-deprived cells initiate HR at a much lower rate than VEGF-enriched cells and 409 
are consistent with a scenario in which VEGF driven activation of Akt promotes rapid 410 
and efficient NHEJ, which also permits functional HR. In the absence of VEGF, lack 411 
of Akt signalling results in aberrant and prolonged binding of DNA-PKcs to DSB 412 
which both delays NHEJ mediated repair and inhibits HR. 413 
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Activation of VEGFR2 and functional activation of both NHEJ and HR in an 415 
orthotopic mouse model of GBM  416 
To validate in vivo the observations made in the 3D model in vitro, we interrogated 417 
relevant DDR parameters before and after irradiation in tissue from patient-derived 418 
human GBM orthotopic mouse models. We have previously shown phosphorylation 419 
and activation of the VEGFR2 receptor in the majority of tumour cells in G7 and E2 420 
orthotopic tumours 14 and  Supplementary Fig. S4A, confirming that VEGF/VEGFR2 421 
signalling is active in vivo. Based on our 3D in vitro data, we hypothesised that 422 
tumour cells in which VEGF signalling pathway is active would exhibit functional 423 
NHEJ and that pDNA-PKcs nuclear foci would be detectable at early time points 424 
after irradiation in vivo and would resolve rapidly. To assess this, CD1 nude mice 425 
were injected intracranially with E2 cells and monitored for five months to allow the 426 
infiltrative tumour growth pattern characteristic of this model. Following this period, 427 
mice underwent partial brain irradiation (10Gy) or mock treatment and were 428 
sacrificed at different time points (0, 0.5, 2 and 24 h). Immunofluorescence was 429 
performed to evaluate activation of NHEJ by detection of pDNA-PKcs nuclear foci. 430 
For this experiment, EGFR was selected as tumour cell marker as it was not 431 
expressed in normal mouse brain tissue (Supplementary Fig. S4A). A significant 432 
increase in pDNA-PKcs foci was detected 30 minutes after radiation treatment, the 433 
vast majority of which had resolved within 2 hours. No foci were detected at the 24 434 
hour time point (Fig. 6A). Consistent with these data, Rad51 nuclear foci were 435 
detected 4 hours after radiation treatment in vivo and had resolved by 24 hours 436 
(Supplementary Fig. S4B).  These data recapitulate our in vitro observations, where 437 
3D GSC grown in the presence of VEGF activated Akt and exhibited efficient DSB 438 
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repair, with early NHEJ activation followed by HR activation and complete resolution 439 
of repair foci by 24 hours.  440 
MK-2206 extends survival in combination with radiation in the  U87MGLuc 441 
orthotopic xenograft GBM model 442 
We then proceeded to evaluate the efficacy of combining Akt inhibition with radiation 443 
in vivo. CD1 nude mice were injected intracranially with U87MGLuc cells. 444 
Bioluminescence imaging was performed on day 6 confirming tumour engraftment 445 
(Supplementary Fig. S4C).  At day 13, mice were randomised into 4 cohorts (Fig. 446 
6B), and treated with respective protocols over a two-week period.  All treatment 447 
regimens were well tolerated, with no significant changes in body weight observed 448 
(Fig. 6C).  Following this period, mice were monitored daily and sacrificed when 449 
symptomatic. While no increase in survival was conferred by the Akt inhibitor MK-450 
2206 alone, the radiation schedule of 6 x 2 Gy (administered on alternate days) was 451 
associated with a modest but statistically significant increase in survival (P < 0.001), 452 
and combined treatment with MK-2206 and radiation conferred additional survival 453 
benefit, with a 9-day prolongation in median survival over control or MK-2206 alone 454 
(P < 0.0001) and a 5-day prolongation in median survival relative to the IR schedule 455 
(P = 0.006; Fig. 6D and E,  Supplementary Table S3). 456 
Erlotinib treatment of VEGF-deprived 3D GSC increases their radiation 457 
resistance  458 
While performing clonogenic assays with different treatment combinations, we 459 
observed that erlotinib had a marked radioprotective effect on VEGF-deprived 3D 460 
cultures in three different patient-derived cell lines (G7, E2, and R10), an effect of the 461 
same magnitude as that observed for VEGF treatment in this model (Fig 7A and  462 
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Supplementary Fig. S5A).  No further radioprotection was detected in the presence 463 
of VEGF (Fig. 7A), indicating a correlation between VEGF signalling and EGFR 464 
inhibition that has not been documented previously.  In contrast, radiosensitisation of 465 
2D cultures by erlotinib was not affected by VEGF (Supplementary Fig. S5B-D).  466 
Consistent with these results, the radioresistant erlotinib-treated 3D GSC and the 3D 467 
GSC supplemented with VEGF were more efficient at repairing DSBs after radiation 468 
treatment, exhibiting lower number of H2AX foci levels at 24 hrs than the 469 
radiosensitive 3D VEGF-deprived cells (Supplementary Fig. S5E).  No statistically 470 
significant difference was observed in the number of pDNA-PKcs foci and Rad51 foci 471 
were observed in the erlotinib-treated VEGF-deprived 3D GSC (Fig. 7B and 7C) and 472 
in erlotinib-treated VEGF supplemented 3D GSC (Supplementary Fig. S5F and S5G) 473 
as in the VEGF-treated cells at early time points, which were completely resolved at 474 
24 hrs, in contrast to the VEGF-deprived cells without erlotinib which exhibited 475 
increased pDNA-PKcs foci at all timepoints and reduced Rad51 foci. 476 
EGFR/DNA-PKcs nuclear colocalisation correlates with aberrant NHEJ and HR 477 
in VEGF-deprived radiosensitive populations  478 
Having made the novel and unexpected observation that EGFR inhibition protected 479 
3D GSCs following ionising radiation, we investigated the mechanisms involved. In 480 
head and neck carcinomas, EGFR activates repair of radiation induced DSB through 481 
phosphorylation of DNA-PKcs [35, 36]. Colocalisation analysis of DNA-PKcs and 482 
EGFR was therefore performed in G7 and E2 3D cultures in the radioresistant 483 
populations (+VEGF or erlotinib) and the radiosensitive VEGF-deprived cells.  484 
Nuclear colocalisation of DNA-PKcs and EGFR was detected in the VEGF-deprived 485 
radiosensitive 3D populations at both early (0.5 hours) and late (24 hours) timepoints 486 
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after radiation treatment.  In contrast, nuclear colocalisation of DNA-PKcs and EGFR 487 
could not be observed in the radioresistant G7 3D (Fig. 7D-F) or E2 3D 488 
(Supplementary Fig. S5H) populations either before or after irradiation. These 489 
findings suggest that, in a clinically relevant 3D model of GBM: (i) VEGF inhibits 490 
nuclear localisation of EGFR, (ii) EGFR activation is required for its translocation into 491 
the nucleus, and (iii) EGFR/DNA-PKcs complex binding to DSBs requires additional 492 
signalling that promotes its disassociation and functional DSB repair.   493 
 494 
Discussion 495 
Here we describe a novel role for VEGF/VEGFR2 signalling in the regulation of 496 
radiation sensitivity and the DDR using a customised, 3D cell culture system that 497 
resembles key histological features of GBM and replicates particular clinical 498 
responses to molecular targeted therapies such as EGFR inhibition and 499 
temozolomide treatment. Our results provide important insights into the mechanisms 500 
by which GSC survive radical radiotherapy. Anti-VEGF therapy (bevacizumab) was 501 
developed primarily to target angiogenesis; our 3D model identifies a direct effect of 502 
VEGF on tumour cell radiosensitivity that could be exploited to overcome radiation 503 
resistance. Credence for the clinical efficacy of targeting VEGF signalling in GBM is 504 
provided by recently reported results of a phase II study of the VEGFR, FGFR and 505 
PDGFR inhibitor regorafenib in patients with recurrent disease, which showed 506 
improved 12 month overall survival (38.9% vs 15.0%) and 6 month progression-free 507 
survival (16.9% vs 8.3%) compared with lomustine 54. A number of potential 508 
resistance mechanisms may explain the failure of bevazicumab to extend survival in 509 
first line treatment (39), including failure to cross the blood brain barrier and 510 
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compensatory roles of other VEGFs (e.g. VEGF-B) or VEGF receptors. More 511 
specifically, GSC have been shown to exhibit a VEGF/VEGFR2 autocrine signalling 512 
loop associated with a cytosolic VEGFR2 subfraction 37, which might contribute to 513 
resistance to VEGF targeting strategies. Our results indicate that tyrosine kinase 514 
receptor related mechanisms underlying radioresistance of GBM in general and GSC 515 
in particular are worthy of detailed investigation in the future.   Further assessment in 516 
the 3D model of successful and failed molecular therapies in the clinic will provide 517 
meaningful validation of the 3D model for utilisation in preclinical studies of molecular 518 
targeted therapies that might predict translational success.  519 
Radioresistance is intimately associated with the DDR, and efficiency and integrity of 520 
DSB repair depends on appropriate engagement of NHEJ and/or HR.  An increasing 521 
body of evidence indicates that cancer cells might be susceptible to aberrant DSB 522 
repair as a consequence of over-expression or inappropriate activation of NHEJ 523 
proteins including the catalytic subunit DNA-PKcs 51,52. While EGFR signalling has 524 
been shown to modulate DNA DSB repair in general and DNA-PKcs activity in 525 
particular 51,52,55,56, to our knowledge there is no published evidence that VEGF 526 
signalling influences any aspect of DNA repair. Our previous observations with 527 
bevacizumab 14 and the demonstration by Bartek’s group that direct inhibition of 528 
VEGFR2 reduces GSC viability under conditions of radiation-evoked stress, implied 529 
a potential role for VEGF in DNA repair. The data presented here demonstrate for 530 
the first time that VEGF can activate DNA repair via Akt and DNA-PKcs functionality, 531 
a phenomenon that is only observed in 3D conditions. Furthermore, our studies 532 
show for the first time that Akt responds to different cues in 2D and 3D cells.  While 533 
EGFR regulated Akt activity in 2D cultures, VEGF signalling was required for its 534 
activation in the 3D model. Our results are consistent with previous reports that Akt 535 
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signalling to DNA-PK promotes functional NHEJ activity and radioprotection, but in 536 
previous studies conducted in 2D cultures, the link to VEGF signalling was not 537 
appreciated.    538 
Several reports have demonstrated pre-clinical efficacy of the Akt MK-2206 inhibitor 539 
in combination with gefitinib) in mouse models of GBM 57,58.  Indeed, clinical trials 540 
investigating Akt inhibitors in the treatment of GBM are either underway or in 541 
development (e.g. https://clinicaltrials.gov/ct2/show/NCT02430363). Unfortunately a 542 
phase I study of MK-2206 in recurrent GBM was terminated prior to enrolment 543 
following a re-prioritisation process by the pharmaceutical company. Data from our 544 
3D model strongly support the hypothesis that inhibition of Akt will improve clinical 545 
outcomes for GBM and provide further justification for clinical trials in this area. They 546 
also indicate that the interplay between EGFR, VEGFR2, Akt and DNA-PKcs and 547 
possibly other tyrosine kinase receptors such as PDGF and FGFR is worthy of 548 
detailed investigation in the future.  549 
Based on preclinical data, huge amounts of time and money have been devoted to 550 
clinical studies targeting EGFR in the treatment of GBM, none of which has been 551 
successful. In phase I/II clinical trials, addition of erlotinib to radiotherapy and 552 
temozolomide failed to improve outcomes 21,22 and in some cases yielded worse 553 
outcomes26. The identification in 2D breast and pancreatic cell culture systems of 554 
radiation-specific phosphorylation sites of EGFR (Y845 and T654)59 that induce its 555 
translocation to the nucleus and stimulate activation of DNA-PKcs provided a 556 
detailed rationale and mechanism of action for combining EGFR inhibitors with 557 
radiation. Nuclear translocation of EGFR was observed after radiation treatment in 558 
VEGF-deprived, radiosensitive 3D cultures as opposed to VEGF supplemented, 559 
radioresistant cell populations suggests important cross-talk between EGFR and 560 
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VEGFR signalling  in the 3D context and warrants further investigation. More 561 
generally, discrepancies between the EGFR signalling effects observed in our 3D 562 
cultures and those described in previous reports might explain the failure of 563 
simplified 2D preclinical models to predict the negative outcomes of clinical trials.   564 
In summary, irradiation of GBM stem-like cells in a novel 3D cell culture system has 565 
radiosensitisation and revealed previously unreported radioprotective effects of 566 
VEGF that are mediate through the NHEJ and HR DNA repair pathways (Fig. 7G). 567 
As well as increasing our understanding of the clinical effects and limitations of 568 
radiation therapy in the management of patients with GBM, these data support the 569 
clinical evaluation of Akt inhibitors in GBM and reinforce the concept that potential 570 
treatments for GBM should be evaluated in more representative 3D models before 571 
proceeding to in vivo and clinical testing.   572 
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Figure legends 745 
Figure 1.  Radiosensitisation of GSC is determined by growth conditions.  A-B, 746 
Clonogenic efficiency (A) and survival (B) of G7, E2 and R10 GSC grown in 2D and 747 
3D conditions with or without VEGF (3 ng/ml) and irradiated with single doses of X-748 
rays (0-6 Gy; n=3).  VEGF deprivation significantly increased radiosensitivity of G7, 749 
E2 and R10 GSC under 3D conditions (two way ANOVA; p =0.0009, p =0.0056, and 750 
p <0.0001, respectively).  No significant effect of VEGF was observed in 2D 751 
conditions. C, Western blot analysis of G7 GSC grown in 2D or 3D conditions and 752 
treated with IR (5 Gy) and/or erlotinib (1 M) at the indicated time points. Actin 753 
served as loading control. D, Clonogenic survival curves as in (B).  Cells were 754 
treated with erlotinib (1 M) for 2 h and then irradiated at different radiation doses (0-755 
6 Gy).  All cell lines grown in 2D conditions were significantly radiosensitised by 756 
erlotinib (2-way ANOVA analysis: G7 p < 0.0001, E2 p < 0.001 , R10 p < 0.01). No 757 
radiosensitisation was conferred upon 3D GSC by erlotinib.  758 
Figure 2.  Akt regulates EGFR and VEGF radiosensitivity in 2D and 3D GSC, 759 
respectively. A, G7 and E2 cells grown in 2D or 3D conditions were growth factor-760 
starved for 48 hours followed by addition of EGF (10 ng/ml) or VEGF (3 ng/ml).  Cell 761 
extracts were prepared at the indicated time points and analysed for total and 762 
phospho-EGFR (Y1173) and total and phospho-Akt (S473). S = serum starved; GF = 763 
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+EGF and +VEGF for 6 hours. Actin served as loading control. B, Protein extracts of 764 
G7 (upper blots) and E2 GSCs (lower blots) grown in 2D and 3D conditions in the 765 
presence of VEGF and treated for 2 hrs with erlotinib  at a range of concentrations 766 
(0.5 to 5 M) followed by radiation treatment (5 Gy) or mock-irradiation.  Lysates 767 
were prepared 1 hour after irradiation and  analysed for total and phosphorylated 768 
EGFR and Akt. C, E2 GSCs grown in 2D and 3D conditions in the presence of VEGF 769 
were treated with vehicle (DMSO) or erlotinib (1 M) for 2 hrs and ionising radiation 770 
(5 Gy) and protein extracts obtained at different time points after irradiation and 771 
analysed as in A. D, G7 and E2 GSC grown in 2D and 3D conditions in the presence 772 
of VEGF were treated with MK-2206 (1 M) for 2 hours mock-irradiated or treated 773 
with ionising radiation (5 Gy). Protein extracts were prepared at different time points.  774 
Samples were analysed for total and activated Akt (pAkt at S473) and H2AX by 775 
Western blot.  Tubulin served as loading control.   776 
Figure 3. Radiosensitisation of GSC by Akt inhibition. A, Clonogenic survival of G7 777 
and E2 GSC grown in 2D conditions and irradiated with single doses of X-rays (0-6 778 
Gy; n=3) 1 h after treatment with DMSO, MK-2206 (1 M) and/or erlotinib (1M).  779 
MK-2206 treatment significantly increased radiosensitivity of G7 and E2 GSC in 2D 780 
(two-way ANOVA; G7 2D vs G7 2D + MK-2206 or G7 2D + erlotinib + MK2206 781 
p<0.0001; E2 2D vs E2 + MK-2206 or E2 2D + MK-2206 + erlotinib p <0.0001, E2 782 
2D vs E2 + erlotinib p = 0.0006). B, Clonogenic survival of G7 and E2 GSC grown in 783 
3D in conditions as in (A). MK-2206 treatment significantly increased radiosensitivity 784 
of G7 and E2 GSC in 3D conditions (two-way ANOVA; G7 3D vs G7 3D + MK-2206 785 
(+) VEGF or G7 3D + MK2206 (-) VEGF p<0.0001; E2 3D vs all other conditions p 786 
<0.0001.) C, MK-2206 dose response (0.1 M to 10 M) at 0 and 3 Gy in G7 3D 787 
GSC.  Each curve is normalised to respective vehicle plus radiation dose.  D, Cell 788 
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lysates from E2 cells transfected with siRNA against Akt1, Akt3 or Scramble were 789 
analysed for expression of total Akt1, Akt3 after 48 h incubation. Tubulin served as 790 
loading control. E, Clonogenic assays were performed from E2 cells previously 791 
transfected with Scramble or Akt1-3 siRNAs.  Akt siRNA cells exhibited increased 792 
radiosensitivity compared to Scramble siRNA (two-way ANOVA; siRNA Scramble v 793 
all three siRNA Akts p < 0.0001).  794 
Figure 4. VEGF deprivation and Akt inhibition reduce DNA double strand break 795 
repair following irradiation,of 3D GSC.  A, Representative immunofluorescent images 796 
for H2AX foci of G7 GSC grown in 3D conditions before (0 h) or after (24 h) ionising 797 
radiation (5 Gy) in the presence [(+) VEGF] or absence of VEGF [(-) VEGF].  B-F, 798 
Quantification of H2AX foci per nucleus following radiation treatment (5 Gy, B, D 799 
and E; or 0 Gy, C and F) in the presence or absence of VEGF (B and C); or DMSO 800 
or MK-2206 (D-F). Median ± SD from 3 independent experiments. P values 801 
calculated by t test (* p <0.01; ** p <0.001). G, Representative images of 3D cells 802 
before and 24 h after irradiation, immunostained for the mitotic marker phospho-S10 803 
histone H3 (green) to visualise mitotic cells.  DAPI was used to stain for DNA (blue).  804 
Red arrows indicate cells undergoing mitotic catastrophe. H, Percentages of cells 805 
displaying micronuclei, mitosis or mitotic catastrophe.  An average of 350 806 
cells/condition/experiment were identified randomly and scored. Mean ± SEM of 3 807 
independent experiments. P values calculated by t test. 808 
Figure 5.  Functional DNA-PKcs activity correlates with VEGF treatment and Akt 809 
activity in the 3D model. A and C, Representative immunofluorescent images of E2 810 
GSC grown in 3D conditions and stained for pDNA-PKcs foci (red) at different time 811 
points following ionising radiation (5 Gy) in the presence or absence of VEGF (A); or 812 
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DMSO or MK-2206 (C).  Cells in C were also immunostained for H2AX foci (green). 813 
B, Quantification of pDNA-PKcs foci per nucleus following radiation treatment as in A.  814 
Graphs represent medians from 3 independent experiments.  P values calculated by 815 
t test (* p < 0.01; ** p < 0.001; *** P < 0.0001). D, Clonogenic assays were performed 816 
with E2 cells previously transfected with either scrambled or DNA-PKcs siRNA for 48 817 
hrs. Transfected cells were treated with MK-2206 (1 M) 16 h after clonogenic 818 
seeding, incubated for 2 hrs and irradiated at different doses (0-5 Gy). Cell lysates 819 
from E2 cells transfected with siRNA against DNA-PKcs or Scramble were analysed 820 
for expression of total DNA-PKcs after 48 hrs incubation. Tubulin served as loading 821 
control. E, Representative immunofluorescent images of G7 GSC grown in 3D 822 
conditions for Rad51 foci at 3 hrs following ionising radiation (5 Gy) in the presence 823 
or absence of VEGF. F, Quantification of Rad51 foci per nucleus following radiation 824 
treatment.  Graph represents mean of medians from 3 independent experiments.  p 825 
values calculated by t test. 826 
Figure 6. Akt inhibition extends survival of irradiated mice bearing orthotopic glioma 827 
xenografts. A, Representative immunofluorescent images of paraffin-embedded 828 
brains bearing E2 orthotopic tumour cells in mice for pDNA-PKcs S2056 (green).  829 
EGFR (red) was used as tumour marker.  Mice implanted with E2 cells for 5 months 830 
were treated with radiation (10 Gy) and sacrificed at the indicated time points.  B, 831 
Diagram of U87MGLuc2 orthotopic efficacy study, depicting treatment schedules (15 832 
mice/cohort).  C, Graph depicting mouse body weight monitored from cell 833 
implantation until end of treatment.  Mice bearing orthotopic xenografts (U87-MGLuc, 834 
13 days after implantation) were randomized into 4 cohorts and treated with the 835 
protocols shown in B. D, Kaplan-Meier survival curves were generated and analysed 836 
for log-rank. E, Box plot graph of median survival of each treatment group, * p < 0.05, 837 
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** p < 0.001, *** p < 0.0001, by one-way ANOVA original FDR method, multiple 838 
comparison test. 839 
Figure 7. Erlotinib radioprotects VEGF-deprived 3D GSC by blocking EGFR/DNA-840 
PKcs nuclear co-localisation.  A, Clonogenic survival of E2 and G7 GSC grown in 3D 841 
conditions and irradiated with single doses of X-rays (0-6 Gy; n=3) 2 hours after 842 
treatment in the presence (+)VEGF or absence (-)VEGF of VEGF and erlotinib (1M) 843 
or vehicle (DMSO).  Mean±SD of 3 independent experiments is shown; curves are 844 
fitted to a linear quadratic model.  Erlotinib significantly radioprotected VEGF-845 
deprived cells (two-way ANOVA; G7 3D (-) VEGF vehicle vs G7 3D (-) VEGF plus 846 
erlotinib p<0.0001, E2, p=0.01).  No significant effect of erlotinib was observed in the 847 
presence of VEGF. B and C, Quantification of pDNA-PKcs (B) and Rad51 foci (C) 848 
per nucleus following radiation treatment.  Graph represents mean of medians from 849 
3 independent experiments.  p values calculated by t test (* p <0.01; ** p <0.001).D, 850 
Representative immunofluorescent images for EGFR (EGFR) and DNA-PKcs (DNA-851 
PKcs) of G7 3D cells following ionising radiation treatment and fixed with 852 
paraformaldehyde at the indicated time points (0, 0.5 and 24 hrs).  Cells were treated 853 
with erlotinib in the absence or presence of VEGF. E, Representative 854 
immunofluorescent images for the co-localisation of DNA-PKcs and EGFR using Zen 855 
Black software by selecting nuclei as regions of interest (red circles) and using the 856 
Cut Mask tool following selection and generation of a new image which sets every 857 
pixel outside the colocalised pixels to zero and exposing only the pixels where tDNA-858 
PKcs / tEGFR signals are expressed in the same pixel. F, Quantification of DNA-859 
PKcs and EGFR colocalisation per nucleus in G7 3D GSC.  Approximately 40 nuclei 860 
were quantified for each condition.  Box and whisker plots represent median number 861 
of signal per nucleus, p values calculated by Mann Whitney U test (*p<0.05; 862 
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**p<0.005). G, Graphic representation of glioblastoma responses to EGF and VEGF 863 
signalling in 2D and 3D conditions, respectively, with Akt acting as the main switch 864 
between NHEJ and HR resulting in radiation sensitization (aberrant NHEJ) or 865 
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